Key Takeaways:
Nanobiotix SA and partner Johnson & Johnson reported a 57.1% complete response rate in a small study of patients with inoperable Stage 3 lung cancer, a figure that dramatically exceeds the less than 5% rate for the current standard of care. The data for the nanoradioenhancer, JNJ-1900, was presented at the 2026 European Society for Radiotherapy and Oncology (ESTRO) Annual Meeting.
"Early results suggest that intratumoral/intranodal injection of JNJ-1900 (NBTXR3) is feasible and can be performed safely in patients with stage III unresectable NSCLC," the study's authors concluded in the presentation.
In the seven patients who received the full treatment regimen, the therapy achieved an 85.7% overall response rate (six of seven patients) and a 100% disease control rate, according to the Part 1 data from the Phase 2 CONVERGE trial. The full regimen consisted of the JNJ-1900 injection combined with concurrent chemoradiotherapy and subsequent consolidation therapy with the checkpoint inhibitor durvalumab.
The results offer a glimpse of the high-efficacy potential for Nanobiotix's technology platform, yet the company’s stock (NASDAQ: NBTX) fell 6.48% to $51.50 on the day of the announcement. The negative reaction may reflect investor caution given the very small number of patients in the initial data set, even as the partnership with Johnson & Johnson provides significant validation and development support.
JNJ-1900, also known as NBTXR3, is a suspension of functionalized hafnium oxide nanoparticles administered via a one-time injection directly into a tumor. The nanoparticles are designed to be inert until activated by standard radiotherapy. Once activated, they concentrate radiation energy within the tumor, leading to greater cancer cell destruction than with radiotherapy alone. The company believes this localized cell death can also trigger a systemic immune response, helping the body fight cancer cells elsewhere.
The more than 6% drop in Nanobiotix shares runs counter to the stock's historical trend, where clinical trial updates for NBTXR3 have typically prompted positive price moves. The small, seven-patient sample size from this Part 1 readout is likely the primary reason for the market's tempered enthusiasm, as investors await data from a larger cohort to confirm the durability and replicability of these impressive early results.
The lung cancer program is part of a broad development strategy for NBTXR3, which is being evaluated in multiple solid tumors. The lead program is a global Phase 3 trial, NANORAY-312, targeting patients with locally advanced head and neck squamous cell cancers. Success in that larger, later-stage trial will be critical for the company's future.
This article is for informational purposes only and does not constitute investment advice.
